

Plan to Cover Anti-Obesity Drugs Through Medicare Rejected by Trump Administration

Healthcare Law Update

Plan to Cover Anti-Obesity Drugs Through Medicare Rejected by Trump Administration

Joseph M. Gorrell
Member, Healthcare

Jonathan J. Walzman
Member, Healthcare

Paul DeMartino, Jr.
Counsel, Healthcare

BRACH | EICHLER^{LLC}
Counsellors at Law

5/1/2025

The Trump administration recently declined to finalize portions of a [rule](#) proposed by the Biden administration in November 2024 for Medicare coverage of obesity drugs, such as GLP-1 medications Wegovy and Zepbound. Medicare does cover weight-loss drugs for conditions like diabetes and cardiovascular disease. Additionally, some states cover weight loss drugs in their Medicaid programs. An October 2024 [report](#) by the Congressional Budget Office, warned that authorizing these anti-obesity treatments for Medicare coverage would increase federal spending by approximately \$35 billion from 2026 to 2034, while the total savings from improved health would be small, totaling under \$50 million in 2026 and around \$1 billion in 2034.

[Click Here to read the entire May 2025 Healthcare Law Update now!](#)

For more information, contact:

Joseph M. Gorrell | 973.403.3112 | jgorrell@bracheichler.com

Jonathan J. Walzman | 973.403.3120 | jwalzman@bracheichler.com

Paul DeMartino, Jr. | 973.364.5228 | pdemartino@bracheichler.com

Authors

The following attorneys contributed to this insight.



Joseph M. Gorrell

Member
Healthcare Law

973.403.3112 · 973.618.5512 Fax
jgorrell@bracheichler.com



Jonathan J. Walzman

Member
Healthcare Law, Corporate
Transactions & Financial Services

973.403.3120 · 973.618.5561 Fax
jwalzman@bracheichler.com



Paul J. DeMartino, Jr.

Counsel
Healthcare Law, Litigation

973.364.5228 · 973.860.4221 Fax
pdemartino@bracheichler.com